|Bid||66.30 x 900|
|Ask||73.09 x 1200|
|Day's range||69.10 - 73.57|
|52-week range||68.44 - 127.42|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||244.86|
|Earnings date||07 Mar 2022 - 11 Mar 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||121.00|
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...
Huge gains could be up ahead if the rest of the market sees these stocks in the same light as investment bank analysts.
Stock market investing is easier than ever, even if you don't have heaps of cash lying around in your brokerage account. Carefully monitoring organ transplant recipients for initial signs of rejection can save healthcare plan sponsors a bundle. Until CareDx (NASDAQ: CDNA) came along, though, deciding how heavily to compromise a patient's immune system involved a lot of guesswork.